ITK Pipeline Spotlight: Guggenheim Initiates Buy on Aclaris Therapeutics
Guggenheim rates ACRS Buy, $12 target vs $4.50 now; skin/immune drugs, trials ahead, big upside if results are good.
/ 2 items
Guggenheim rates ACRS Buy, $12 target vs $4.50 now; skin/immune drugs, trials ahead, big upside if results are good.
Craig-Hallum initiates coverage of Aclaris Therapeutics with a Buy rating and $10 target, noting upcoming 2026 readouts and potential in ATI-052.